Upper endoscopy for the removal of an abnormal tissue of the upper gastrointestinal tract is frequently reported using CPT 43251. The accuracy of coding relies on the proper documentation of the location of the lesion, how it was removed and the medical necessity for the intervention.
Complete removal of the lesion should be documented with a snare technique and not with biopsy or hot biopsy forceps, as therapeutic endoscopic procedures are often reviewed by payers. Compliance and claim denials are lessened with thorough documentation.
For practices that use Gastroenterology Billing Services, there is a potential to benefit from coding review and documentation validation processes that can help guarantee claim accuracy and help improve reimbursement performance.
CPT 43251 Description
Official Definition:
"Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique."
CPT 43251 describes a therapeutic upper gastrointestinal endoscopy in which a flexible endoscope is advanced through the mouth to examine the esophagus, stomach, and duodenum. During the procedure, one or more tumors, polyps, or other lesions are removed using a snare device that encircles and excises the targeted tissue.
The snare technique may utilize electrocautery to facilitate removal and control bleeding. The diagnostic EGD portion is included in the code and should not be reported separately.
The service includes
- Flexible transoral esophagogastroduodenoscopy (EGD)
- Examination of the esophagus, stomach, and duodenum
- Identification of tumors, polyps, or other lesions
- Removal of one or more lesions using a snare technique
- Retrieval of excised tissue when performed
- Assessment of the treatment site following removal
However, CPT 43251 does not include
- Separate reporting of the diagnostic EGD
- Simple tissue biopsy
- Lesion removal using hot biopsy forceps
- The ability of patients to control bleeding without removing lesions
- Endoscopic ablation procedures
Clinical Indications for CPT 43251
CPT 43251 is typically reported when abnormal tissue within the upper gastrointestinal tract requires therapeutic removal. The procedure may be performed to treat symptoms, prevent complications, or obtain complete excision of suspicious lesions.
Common indications include
- Gastric polyps
- Duodenal polyps
- Esophageal polyps
- Benign gastrointestinal tumors
- Stomatitis and upper GI lesions, especially those that are suspicious.
- Symptoms resulting in bleeding lesions
- The amount of tissue that is obstructed because of lesions.
- The results of surveillance for which the children must be removed.
The procedure may also be performed when abnormal growths are identified during diagnostic endoscopy and immediate removal is clinically appropriate.
Reimbursement Insights for CPT 43251
CPT code 43251 is typically reimbursed based on the therapeutic use of the procedure and the medical necessity associated with the removal of lesions. Documentation should be clear that the lesion was removed as opposed to sampled with biopsy alone.
Key reimbursement considerations
- Medically necessary and covered by Medicare and most commercial payers.
- Reimbursement is usually greater for reimbursable services than diagnostic EGD services.
- Global period: 000 days
- Diagnostic EGD is bundled into CPT 43251
- Multiple lesions removed using the same technique during a single session are typically reported with one unit of service
- Payment varies according to payer contracts, geographic region, and site of service
- Separate facility reimbursement could be available for hospital outpatient departments and ASCs.
Applicable Modifiers for CPT 43251
The modifier should accurately represent the circumstances of the procedure and any services rendered during the same encounter. All modifiers should be supported with documentation.
Common modifiers
- Modifier -51: Used when two or more procedures are done in the same operative session.
- Modifier -59 or X{EPSU}: Used when a separate procedural service is provided at a separate site or under different circumstances that warrant separate reporting.
- Modifier -22: Used when the procedure requires substantially greater effort than normally expected and supporting documentation is provided.
- Modifier -52: Used when the planned service is partially reduced.
- Modifier -53: Used when the procedure is discontinued due to patient safety concerns or technical limitations.
- Modifier -78: Used for an unplanned return to the procedure room during the postoperative period.
- Modifier -79: Used when an unrelated procedure is performed during the postoperative period.
Important billing rule
CPT 43251 includes the diagnostic EGD component and should not be reported with CPT 43235 during the same procedure session.
Documentation Requirements for CPT 43251
Completing documentation is vital for code selection, medical necessity and payer compliance. The procedure report should provide a clear description of the lesion and be sure to document that the lesion was snared.
Documentation should include
- Medical indication for lesion removal
- Location of each lesion
- Number of lesions removed
- Size and appearance of lesions when documented
- Snare removal technique utilized
- Use of electrocautery when applicable
- Specimen retrieval details
- Findings Conclusions after the removal of lesions.
- Any complications or bleeding that occurs
- Patient's acceptability of procedure.
- Final procedure report, signed.
Documentation should clearly distinguish lesion removal from diagnostic biopsy procedures to support accurate code assignment.
Example Clinical Scenarios
Scenario 1: Gastric Polyp Removed by Snare Technique
Upper endoscopy is performed in a 63-year-old patient who had previously had an imaging test and a gastric polyp was found. The gastroenterologist extracts the polyp with a snare device during EGD, and takes the polyp for pathological examination.
→ Coding Outcome: CPT 43251
→ Rationale: A gastric lesion was excised via EGD snare.
Scenario 2: Duodenal Polyp Excision During Endoscopy
A patient comes for surveillance endoscopy because of past history of gastrointestinal polyps. During the examination, a duodenal polyp is identified and completely removed using snare excision.
→ Coding Outcome: CPT 43251
→ Rationale: Therapeutic removal of a duodenal lesion by snare technique supports CPT 43251.
Scenario 3: Esophageal Lesion Removed for Pathologic Evaluation
At the upper endoscopy, a suspicious lesion in the esophagus is found. Then the doctor completely removes the snare from the lesion and submits the specimen to the pathologist for evaluation.
→ Coding Outcome: CPT 43251
→ Rationale: Esophageal lesion was completely excised by snare technique.
Scenario 4: Procedure Discontinued Due to Bleeding Risk
Planned removal of a large lesion in the stomach using a snare. Partial treatment is performed, and a significant bleeding risk is noted, and the doctor decides to discontinue the procedure prior to complete removal.
→ Coding Outcome: CPT 43251-53
→ Rationale: Procedure discontinued prior to completion for patient safety reasons, supported by modifier -53.
BillingFreedom Driving 97%+ First-Pass Claim Accuracy in GI Billing
BillingFreedom's team provides support for gastroenterology practices to improve the accuracy and completeness of coding for therapeutic endoscopy where detailed documentation and careful code selection are crucial. When performing services that require lesion removal, it is important to distinguish between biopsy, excision and snare procedures to ensure appropriate reimbursement.
Our billing specialists are dedicated to reviewing procedural documentation prior to claim submission to help practices eliminate procedural coding inconsistencies and avoid unnecessary claim problems. We integrate with clinical reporting requirements, helping you to ensure that billing cycles are seamless and reimbursement is optimized.
Key Revenue Cycle Performance Metrics
BillingFreedom ensures code accuracy and compliance with standards while prioritizing performance in billing processes to maximize reimbursement efficiency.
- High first-pass claim acceptance rate, consistently at 97% – 99%, which facilitates quicker claim resolution.
- Maintain Preventable denial rate at below 1%, which helps to safeguard the practice revenue.
- Clean claim submission accuracy exceeding 95%, improving payer acceptance rates
- Internal coding validation accuracy above 98%, supporting documentation and coding consistency
- Continuous quality review processes which reduce billing errors and claim corrections
This approach ensures gastroenterology practices are more efficient and more likely to have a successful reimbursement experience.
Discover more about our Gastroenterology Billing Services and how we can support GI practices achieve accurate coding and better reimbursement outcomes.
For more details about our Gastroenterology medical billing services, please don't hesitate to contact us by email at info@billingfreedom.com or call us at +1 (855) 415-3472.
It is our top priority to give you financial peace of mind!
Related ICD-10-CM Codes
ICD-10-CM Codes
C15.3 - Malignant neoplasm of upper third of esophagus
C15.4 - Malignant neoplasm of middle third of esophagus
C15.5 - Malignant neoplasm of lower third of esophagus
C15.8 - Malignant neoplasm of overlapping sites of esophagus
C16.1 - Malignant neoplasm of fundus of stomach
C16.2 - Malignant neoplasm of body of stomach
C16.3 - Malignant neoplasm of pyloric antrum
C16.4 - Malignant neoplasm of pylorus
C16.5 - Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6 - Malignant neoplasm of greater curvature of stomach, unspecified
C16.8 - Malignant neoplasm of overlapping sites of stomach
C17.1 - Malignant neoplasm of jejunum
C17.8 - Malignant neoplasm of overlapping sites of small intestine
C49.A0 - Gastrointestinal stromal tumor, unspecified site
C49.A1 - Gastrointestinal stromal tumor of esophagus
C49.A2 - Gastrointestinal stromal tumor of stomach
C49.A3 - Gastrointestinal stromal tumor of small intestine
C49.A4 - Gastrointestinal stromal tumor of large intestine
C49.A5 - Gastrointestinal stromal tumor of rectum
C49.A9 - Gastrointestinal stromal tumor of other sites
C78.4 - Secondary malignant neoplasm of small intestine
C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80 - Secondary malignant neoplasm of unspecified digestive organ
C78.89 - Secondary malignant neoplasm of other digestive organs
C7A.010 - Malignant carcinoid tumor of the duodenum
C7A.011 - Malignant carcinoid tumor of the jejunum
C7A.092 - Malignant carcinoid tumor of the stomach
C7A.094 - Malignant carcinoid tumor of the foregut, unspecified
D00.2 - Carcinoma in situ of stomach
D01.40 - Carcinoma in situ of unspecified part of intestine
D01.49 - Carcinoma in situ of other parts of intestine
D13.1 - Benign neoplasm of stomach
D13.2 - Benign neoplasm of duodenum
D13.30 - Benign neoplasm of unspecified part of small intestine
D13.39 - Benign neoplasm of other parts of small intestine
D13.99 - Benign neoplasm of ill-defined sites within the digestive system
D37.1 - Neoplasm of uncertain behavior of stomach
D37.2 - Neoplasm of uncertain behavior of small intestine
D37.3 - Neoplasm of uncertain behavior of appendix
D37.4 - Neoplasm of uncertain behavior of colon
D37.5 - Neoplasm of uncertain behavior of rectum
D37.8 - Neoplasm of uncertain behavior of other specified digestive organs
D37.9 - Neoplasm of uncertain behavior of digestive organ, unspecified
D3A.011 - Benign carcinoid tumor of the jejunum
D3A.094 - Benign carcinoid tumor of the foregut, unspecified
D3A.098 - Benign carcinoid tumors of other sites
F50.010 - Anorexia nervosa, restricting type, mild
F50.011 - Anorexia nervosa, restricting type, moderate
F50.012 - Anorexia nervosa, restricting type, severe
F50.013 - Anorexia nervosa, restricting type, extreme
F50.014 - Anorexia nervosa, restricting type, in remission
F50.019 - Anorexia nervosa, restricting type, unspecified
F50.020 - Anorexia nervosa, binge eating/purging type, mild
F50.021 - Anorexia nervosa, binge eating/purging type, moderate
F50.022 - Anorexia nervosa, binge eating/purging type, severe
F50.023 - Anorexia nervosa, binge eating/purging type, extreme
F50.024 - Anorexia nervosa, binge eating/purging type, in remission
F50.029 - Anorexia nervosa, binge eating/purging type, unspecified
F50.20 - Bulimia nervosa, unspecified
F50.21 - Bulimia nervosa, mild
F50.22 - Bulimia nervosa, moderate
F50.23 - Bulimia nervosa, severe
F50.24 - Bulimia nervosa, extreme
F50.25 - Bulimia nervosa, in remission
F50.810 - Binge eating disorder, mild
F50.811 - Binge eating disorder, moderate
F50.812 - Binge eating disorder, severe
F50.813 - Binge eating disorder, extreme
F50.814 - Binge eating disorder, in remission
F50.819 - Binge eating disorder, unspecified
F50.83 - Pica in adults
F50.84 - Rumination disorder in adults
F98.21 - Rumination disorder of infancy and childhood
K22.9 - Disease of esophagus, unspecified
K31.7 - Polyp of stomach and duodenum
K31.811 - Angiodysplasia of stomach and duodenum with bleeding
K31.819 - Angiodysplasia of stomach and duodenum without bleeding
K31.89 - Other diseases of stomach and duodenum
Q85.82 - Other Cowden syndrome
Q85.83 - Von Hippel-Lindau syndrome
Q85.89 - Other phakomatoses, not elsewhere classified
T18.3XXD - Foreign body in small intestine, subsequent encounter
T18.3XXS - Foreign body in small intestine, sequela
T18.8XXD - Foreign body in other parts of alimentary tract, subsequent encounter
T18.9XXD - Foreign body of alimentary tract, part unspecified, subsequent encounter
T18.9XXS - Foreign body of alimentary tract, part unspecified, sequela
T54.1X1D - Toxic effect of other corrosive organic compounds, accidental (unintentional), subsequent encounter
T54.1X1S - Toxic effect of other corrosive organic compounds, accidental (unintentional), sequela
T54.1X2D - Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter
T54.1X2S - Toxic effect of other corrosive organic compounds, intentional self-harm, sequela
T54.1X3D - Toxic effect of other corrosive organic compounds, assault, subsequent encounter
T54.1X3S - Toxic effect of other corrosive organic compounds, assault, sequela
T54.1X4D - Toxic effect of other corrosive organic compounds, undetermined, subsequent encounter
T54.1X4S - Toxic effect of other corrosive organic compounds, undetermined, sequela
T54.2X1D - Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), subsequent encounter
T54.2X1S - Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), sequela
T54.2X2D - Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter
T54.2X2S - Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela
T54.2X3D - Toxic effect of corrosive acids and acid-like substances, assault, subsequent encounter
T54.2X3S - Toxic effect of corrosive acids and acid-like substances, assault, sequela
T54.2X4D - Toxic effect of corrosive acids and acid-like substances, undetermined, subsequent encounter
T54.2X4S - Toxic effect of corrosive acids and acid-like substances, undetermined, sequela
T54.3X1D - Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), subsequent encounter
T54.3X1S - Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), sequela
T54.3X2D - Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter
T54.3X2S - Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela
T54.3X3D - Toxic effect of corrosive alkalis and alkali-like substances, assault, subsequent encounter
T54.3X3S - Toxic effect of corrosive alkalis and alkali-like substances, assault, sequela
T54.3X4D - Toxic effect of corrosive alkalis and alkali-like substances, undetermined, subsequent encounter
T54.3X4S - Toxic effect of corrosive alkalis and alkali-like substances, undetermined, sequela
T54.91XD - Toxic effect of unspecified corrosive substance, accidental (unintentional), subsequent encounter
T54.91XS - Toxic effect of unspecified corrosive substance, accidental (unintentional), sequela
T54.92XD - Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter
T54.92XS - Toxic effect of unspecified corrosive substance, intentional self-harm, sequela
T54.93XD - Toxic effect of unspecified corrosive substance, assault, subsequent encounter
T54.93XS - Toxic effect of unspecified corrosive substance, assault, sequela
T54.94XD - Toxic effect of unspecified corrosive substance, undetermined, subsequent encounter
T54.94XS - Toxic effect of unspecified corrosive substance, undetermined, sequela
T57.1X1D - Toxic effect of phosphorus and its compounds, accidental (unintentional), subsequent encounter
T57.1X1S - Toxic effect of phosphorus and its compounds, accidental (unintentional), sequela
T57.1X2D - Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter
T57.1X2S - Toxic effect of phosphorus and its compounds, intentional self-harm, sequela
T57.1X3D - Toxic effect of phosphorus and its compounds, assault, subsequent encounter
T57.1X3S - Toxic effect of phosphorus and its compounds, assault, sequela
T57.1X4D - Toxic effect of phosphorus and its compounds, undetermined, subsequent encounter
T57.1X4S - Toxic effect of phosphorus and its compounds, undetermined, sequela
T65.5X1D - Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), subsequent encounter
T65.5X1S - Toxic effect of nitroglycerin and other nitric acids and esters, accidental (unintentional), sequela
T65.5X2D - Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, subsequent encounter
T65.5X2S - Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, sequela
T65.5X3D - Toxic effect of nitroglycerin and other nitric acids and esters, assault, subsequent encounter
T65.5X3S - Toxic effect of nitroglycerin and other nitric acids and esters, assault, sequela
T65.5X4D - Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, subsequent encounter
T65.5X4S - Toxic effect of nitroglycerin and other nitric acids and esters, undetermined, sequela
Z86.003 - Personal history of in-situ neoplasm of oral cavity, esophagus and stomach
Z86.004 - Personal history of in-situ neoplasm of other and unspecified digestive organs
Related CPT Codes
CPT Codes
43244 - Complete Billing & Coding Guide for EGD with Band Ligation of Esophageal and Gastric Varices
43245 - Complete Billing & Coding Guide for EGD with Dilation of Gastric or Duodenal Strictures
43248 - Complete Billing & Coding Guide for EGD with Guidewire-Assisted Esophageal Dilation
43249 - Complete Billing & Coding Guide for EGD With Esophageal Balloon Dilation
43254 - Complete Billing & Coding Guide for Endoscopic Mucosal Resection (EMR)
43255 - Complete Billing & Coding Guide for EGD With Control of Bleeding
45384 - Complete Billing & Coding Guide for Colonoscopy with Hot Biopsy Forceps
45385 - Complete Billing & Coding Guide for Colonoscopy with Snare Polypectomy